The relationship between inotrope exposure, six-hour postoperative physiological variables, hospital mortality and renal dysfunction in patients undergoing cardiac surgery

Critical Care

Volumn 15, Issue 4, 2011, Pages

  Shahin, Jason ^a   deVarennes, Benoit ^a   Tse, Chun W ^b   Amarica, Dan Alexandru ^b   Dial, Sandra ^c,d  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; DOBUTAMINE; INOTROPIC AGENT; MILRINONE; CARDIOTONIC AGENT;

ADULT; AGED; AORTA BALLOON; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; FEMALE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SURGERY; HOSPITALIZATION; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPENSITY SCORE; REOPERATION; SIDE EFFECT; CANADA; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY BYPASS GRAFT; HEART VALVE; HEMODYNAMICS; INTENSIVE CARE UNIT; KIDNEY FAILURE; MIDDLE AGED; PHYSIOLOGY; RETROSPECTIVE STUDY; RISK;

AGED; AGED, 80 AND OVER; CARDIOTONIC AGENTS; COHORT STUDIES; CORONARY ARTERY BYPASS; HEART VALVES; HEMODYNAMICS; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MIDDLE AGED; ODDS RATIO; POSTOPERATIVE PERIOD; QUEBEC; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES;

EID: 79959994438     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10302     Document Type: Article

References (26)

1. Ahmed I, House CM, Nelson WB. Predictors of inotrope use in patients undergoing concomitant coronary artery bypass graft (CABG) and aortic valve replacement (AVR) surgeries at separation from cardiopulmonary bypass (CPB). J Cardiothorac Surg 2009, 4:24. 10.1186/1749-8090-4-24, 2706226, 19519919.
2. Gillies M, Bellomo R, Doolan L, Buxton B. Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery: a systematic literature review. Crit Care 2005, 9:266-279. 10.1186/cc3024, 1175868, 15987381.
3. St André AC, DelRossi A. Hemodynamic management of patients in the first 24 hours after cardiac surgery. Crit Care Med 2005, 33:2082-2093. 10.1097/01.CCM.0000178355.96817.81, 16148484.
4. Kastrup M, Markewitz A, Spies C, Carl M, Erb J, Grosse J, Schirmer U. Current practice of hemodynamic monitoring and vasopressor and inotropic therapy in post-operative cardiac surgery patients in Germany: results from a postal survey. Acta Anaesthesiol Scand 2007, 51:347-358. 10.1111/j.1399-6576.2006.01190.x, 17096667.
5. Butterworth JF. Dobutamine: Too dangerous for routine administration?. Anesthesiology 2008, 108:973-974. 10.1097/ALN.0b013e318172fb98, 18497594.
6. Hernandez AF, Li S, Dokholyan RS, O'Brien SM, Ferguson TB, Peterson ED. Variation in perioperative vasoactive therapy in cardiovascular surgical care: data from the Society of Thoracic Surgeons. Am Heart J 2009, 158:47-52. 10.1016/j.ahj.2009.05.014, 19540391.
7. Parissis JT, Rafouli-Stergiou P, Stasinos V, Psarogiannakopoulos P, Mebazaa A. Inotropes in cardiac patients: update 2011. Curr Opin Crit Care 2010, 16:432-441. 10.1097/MCC.0b013e32833e10fb, 20711077.
8. Fellahi JL, Parienti JJ, Hanouz JL, Plaud B, Riou B, Ouattara A. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology 2008, 108:979-987. 10.1097/ALN.0b013e318173026f, 18497597.
9. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure: a meta-regression analysis. Eur J Heart Fail 2002, 4:515-529. 10.1016/S1388-9842(02)00041-7, 12167393.
10. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, . Early Goal-Directed Therapy Collaborative Group Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377. 10.1056/NEJMoa010307, 11794169, Early Goal-Directed Therapy Collaborative Group.
11. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, . Acute Kidney Injury Network Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:R31. 10.1186/cc5713, 2206446, 17331245, Acute Kidney Injury Network.
12. Fleming GA, Murray KT, Yu C, Byrne JG, Greelish JP, Petracek MR, Hoff SJ, Ball SK, Brown NJ, Pretorius M. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. Circulation 2008, 118:1619-1625. 10.1161/CIRCULATIONAHA.108.790162, 2770257, 18824641.
13. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F, DeMets DL, White BG. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998, 339:1810-1816. 10.1056/NEJM199812173392503, 9854116.
14. Cuffe MS, Califf RM, Adams KF, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M, . Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541-1547. 10.1001/jama.287.12.1541, 11911756, Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators.
15. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, . the PROMISE Study Research Group Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991, 325:1468-1475. 10.1056/NEJM199111213252103, 1944425, the PROMISE Study Research Group.
16. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M, . SURVIVE Investigators Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007, 297:1883-1891. 10.1001/jama.297.17.1883, 17473298, SURVIVE Investigators.
17. Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV, Delgado JF, Follath F. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med 2011, 37:290-301. 10.1007/s00134-010-2073-4, 21086112.
18. Giglio MT, Marucci M, Testini M, Brienza N. Goal-directed haemodynamic therapy and gastrointestinal complications in major surgery: a meta-analysis of randomized controlled trials. Br J Anaesth 2009, 103:637-646. 10.1093/bja/aep279, 19837807.
19. Boyd O, Grounds RM, Bennett ED. A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. JAMA 1993, 270:2699-2707. 10.1001/jama.270.22.2699, 7907668.
20. Grocott MPW, Hamilton MA, Bennett ED, Harrison D, Rowan K. Perioperative increase in global blood flow to explicit defined goals and outcomes following surgery. Cochrane Database Syst Rev 2006, 2:CD004082.
21. Kapoor PM, Kakani M, Chowdhury U, Choudhury M, Kiran U. Early goal-directed therapy in moderate to high-risk cardiac surgery patients. Ann Card Anaesth 2008, 11:27-34. 10.4103/0971-9784.38446, 18182756.
22. McKendry M, McGloin H, Saberi D, Caudwell L, Brady AR, Singer M. Randomised controlled trial assessing the impact of a nurse delivered, flow monitored protocol for optimisation of circulatory status after cardiac surgery. BMJ 2004, 329:258. 10.1136/bmj.38156.767118.7C, 498021, 15242867.
23. Pölönen P, Ruokonen E, Hippeläinen M, Pöyhönen M, Takala J. A prospective, randomized study of goal-oriented hemodynamic therapy in cardiac surgical patients. Anesth Analg 2000, 90:1052-1059. 10.1097/00000539-200005000-00010, 10781452.
24. Goepfert MS, Reuter DA, Akyol D, Lamm P, Kilger E, Goetz AE. Goal-directed fluid management reduces vasopressor and catecholamine use in cardiac surgery patients. Intensive Care Med 2007, 33:96-103. 10.1007/s00134-006-0404-2, 17119923.
25. Singer M. Catecholamine treatment for shock-equally good or bad?. Lancet 2007, 370:636-637. 10.1016/S0140-6736(07)61317-8, 17719998.
26. Bastien O, Vallet B, . French Study Group AGIR French multicentre survey on the use of inotropes after cardiac surgery. Crit Care 2005, 9:241-242. 10.1186/cc3482, 1175872, 15987409, French Study Group AGIR.